GSK CEO Emma Walmsley said the pharmaceutical firm has taken precautionary steps to protect its global operations from possible US tariffs on medicines, Bloomberg News reported Friday, citing an interview held in London.

Walmsley told Bloomberg GSK had overhauled its supply chain following the Haleon separation, incorporating backup sourcing to improve operational stability.

She also noted that although GSK is headquartered in the UK, the US accounts for the majority of its business, making it a central focus for investment, the news outlet reported.

Despite policy uncertainty under President Donald Trump, Walmsley reportedly said the company is committed to maintaining a steady flow of treatments and vaccines to patients.

GSK is pursuing expansion in China, especially in infectious disease treatments, but does not manufacture there, limiting its exposure to trade tensions with the US, Bloomberg reported.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)